companydata.dkHemab ApS: Financial statements 2021
CVR: 40837590
Hemab ApS (CVR 40837590) has filed annual accounts for 2021. In 2021, the company reported a net result of DKK -35,163,000. Equity amounted to DKK 68,035,000. The solvency ratio was 86.5%. The company had 3 employees in the financial year.
- Profit/Loss
- -35,163,000 kr.
- Equity
- 68,035,000 kr.
- Total Assets
- 78,696,000 kr.
- Employees
- 3
Find more companies like Hemab ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2021
As of December 16, 2021, EY Godkendt Revisionspartnerselskab has been appointed auditor of Hemab ApS.
As of December 16, 2021, Johnny Kofoed-Jensen Statsautoriseret Revisionsanpartsselskab has stepped down as auditor of Hemab ApS.
As of September 1, 2021, Mads Nikolaj Behrndt-Eriksen is registered as director of Hemab ApS.
As of July 22, 2021, Thomas Dal Stenfeldt Batchelor has joined the board of directors of Hemab ApS.
As of July 22, 2021, Mårten Steen has joined the board of directors of Hemab ApS.
As of July 22, 2021, Laura Anne Tadvalkar has joined the board of directors of Hemab ApS.
As of July 22, 2021, Benny Sørensen has left the board of directors of Hemab ApS.
As of July 22, 2021, Johan Henrik Faber has left the board of directors of Hemab ApS.
As of July 22, 2021, Camilla Petrycer Hansen has left the board of directors of Hemab ApS.
Hemab ApS has published its interim report for the period September 27, 2019 – December 31, 2020.
About Hemab ApS
Hemab ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Ebumab Hemophilia ApS. The management consists of Benny Sørensen and Mads Nikolaj Behrndt-Eriksen. The company is owned by Hemab Therapeutics Holdings, Inc.. Equity amounted to DKK 196,000.